PT  - JOURNAL ARTICLE
AU  - Amir Shlomai
AU  - Ari Leshno
AU  - Ella H. Sklan
AU  - Moshe Leshno
TI  - Cost-effectiveness analysis of social distancing strategies to prevent SARS-CoV2 spread
AID  - 10.1101/2020.03.30.20047860
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.30.20047860
4099  - http://medrxiv.org/content/early/2020/06/05/2020.03.30.20047860.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.03.30.20047860.full
AB  - While highly effective in preventing SARS-CoV-2 spread, global quarantine comes with an enormous economic price. Few countries have adopted an alternative “testing, tracing, and isolation” approach to selectively isolate people at high exposure risk, thereby minimizing the economic impact. However, the cost-effectiveness of these approaches was never tested. A modified Susceptible, Exposed, Infectious, Recovered (SEIR) model was used to test these strategies and the incremental cost-effectiveness ratio (ICER) was calculated. The expected number of deaths under global quarantine is 322 vs. 464 under focused isolation. However, the ICER in the case of global quarantine will be $75,110,000 to prevent one case of death. Thus, global quarantine has a moderate advantage in saving lives with tremendous costs that might result in overwhelming economic effects. These findings should be considered by decision-makers, while preparing for a possible “second wave” of the pandemic or as a lesson for future pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materials